InSightec
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, InSightec sits in the top decile of US sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count).
InSightec: 38 sponsored US clinical trials, 8 recruiting.
InSightec sponsors 38 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 19 completed. 4 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Essential Tremor, with 3 trials.
Top-decile sponsor footprint
InSightec ranks in the top decile of sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
38 total, page 1 of 1
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
NCT05539196
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
NCT05630209
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
NCT04991831
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)
NCT04197921
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
NCT03671889
A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects
NCT03028246
Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids
NCT05386615
Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)
NCT04728295
Bilateral Treatment of Medication Refractory Essential Tremor
NCT04112381
Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions
NCT03998657
ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease
NCT03319485
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
NCT03100474
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
NCT02246374
MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
NCT00147056
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
NCT05383872
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
NCT04417088
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
NCT03551249
ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease
NCT02263885
Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
NCT02289560
Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions
NCT01657942
A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
NCT01833806
ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
NCT01834937
ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
NCT01827904
ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
NCT01772693
ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids
NCT01285960
ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor
NCT01304758
Safety Study of ExAblate for the Treatment of Uterine Fibroids
NCT01142791
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
NCT00981578
ExAblate Treatment of Uterine Fibroids for Fertility Enhancement
NCT00730886
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
NCT00656305
MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication
NCT00365989
MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors
NCT00350233
MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation
NCT00295217
Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids
NCT00131365
MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids
NCT00166270
MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas
NCT00147108
MRI-Guided Ultrasound Energy in Treating Patients With Stage I, Stage II, or Stage IIIA Breast Cancer
NCT00008437
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 4 |
Therapeutic Areas
What is open in the InSightec pipeline
8 recruiting of 38 indexed (21% open); 19 completed (50%).
Phase mix: 4 late (III/IV) vs 5 early (I/II) (balanced across stages).
Top condition: Essential Tremor (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
InSightec: open-pipeline peers nationwide
Peers matched on 38 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
InSightec sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 38 trials (± recruiting share)
- Acerta Pharma · 38 trials · 0% recruiting
- Astex Pharmaceuticals · 38 trials · 0% recruiting
- Corewell Health West · 38 trials · 11% recruiting
- DePuy Orthopaedics · 38 trials · 5% recruiting
Sponsors near 21% open enrollment (± trial volume)
- Nova Southeastern University · 21% recruiting · 71 trials
- Octapharma · 21% recruiting · 43 trials
- Ohio State University · 21% recruiting · 552 trials
- University of Louisville · 21% recruiting · 217 trials
Related
What to do with this InSightec page
38 registered trials is a research-attention snapshot, not an endorsement of InSightec or any single study.
- 8 of InSightec's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Essential Tremor is the condition InSightec studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Essential Tremor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
InSightec pipeline card: 38 registered trials from official public datasets.Report a data error.